Roche's Tecentriq Shows Further Good Survival Rates as Cancer Treatment
17 April 2023 - 3:44PM
Dow Jones News
By Joshua Kirby
Roche Holding AG said Sunday that its tecentriq immunotherapy
drug showed further positive results in an advanced study,
demonstrating significant improvement in recurrence-free survival
in patients.
Tecentriq plus Avastin reduced the risk of recurrence of disease
by 28% in patients with hepatocellular carcinoma at high risk of
recurrence after liver resection or ablation with curative intent,
according to new data from the phase-3 study, the Swiss drugmaker
said.
Recurrence is common in sufferers of HCC, making adjuvant
treatments urgent in order to improve survival rates, said Roche's
chief medical officer, Levi Garraway.
"We are pleased with the potential of these results and look
forward to seeing more mature data," Mr. Garraway said.
The safety data of the phase-3 study were consistent with
relevant profiles, Roche said.
The study earlier this year met its primary endpoint, showing
good recurrence-free survival rates in patients treated with
Tecentriq and Avastin for early-stage HCC.
The drug was meanwhile given the green light by the European
health authorities last year for treatment of some adult sufferers
of small-cell lung cancer.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
April 17, 2023 01:29 ET (05:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024